Tohumcuoğlu, M.; Köşeci, T.; Düşgün, A.; Yetişir, A.E.; Mirili, C.; Mete, B.; Büyükşimşek, M.
Enzalutamide Versus Abiraterone After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Real-World Outcomes and Exploratory Prognostic Stratification. J. Clin. Med. 2026, 15, 4816.
https://doi.org/10.3390/jcm15124816
AMA Style
Tohumcuoğlu M, Köşeci T, Düşgün A, Yetişir AE, Mirili C, Mete B, Büyükşimşek M.
Enzalutamide Versus Abiraterone After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Real-World Outcomes and Exploratory Prognostic Stratification. Journal of Clinical Medicine. 2026; 15(12):4816.
https://doi.org/10.3390/jcm15124816
Chicago/Turabian Style
Tohumcuoğlu, Mert, Tolga Köşeci, Alpay Düşgün, Abdullah Evren Yetişir, Cem Mirili, Burak Mete, and Mahmut Büyükşimşek.
2026. "Enzalutamide Versus Abiraterone After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Real-World Outcomes and Exploratory Prognostic Stratification" Journal of Clinical Medicine 15, no. 12: 4816.
https://doi.org/10.3390/jcm15124816
APA Style
Tohumcuoğlu, M., Köşeci, T., Düşgün, A., Yetişir, A. E., Mirili, C., Mete, B., & Büyükşimşek, M.
(2026). Enzalutamide Versus Abiraterone After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Real-World Outcomes and Exploratory Prognostic Stratification. Journal of Clinical Medicine, 15(12), 4816.
https://doi.org/10.3390/jcm15124816
